表紙
市場調查報告書

全球阿茲海默症診斷及治療藥市場:各治療藥、診斷法、地區 - 成長,趨勢,預測(2018年∼2023年)

Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 661016
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
全球阿茲海默症診斷及治療藥市場:各治療藥、診斷法、地區 - 成長,趨勢,預測(2018年∼2023年) Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 114 Pages
簡介

全球阿茲海默症診斷及治療藥市場,2017年價值71億美元,預計從2018年到2023年以6.7%的年複合成長率發展。各地區中,北美市場佔最大的佔有率。

本報告提供全球阿茲海默症診斷及治療藥市場調查,市場概要,各治療藥、診斷法、地區的市場規模的變化與預測,市場趨勢,市場佔有率,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題分析

  • 成長要素
    • 醫藥品開發的生物標記的投資
    • 開發平台醫藥品的開發擴大
    • 阿茲海默症的罹患率及盛行率的上升
    • 早期發現的先進診斷增加和精密醫藥品的開發
    • 新興診斷技術的崛起
  • 市場阻礙因素
    • 症狀的早期診斷的課題
    • 後期臨床試驗失敗造成的市場衰退
    • 藥物研發和醫藥品開發的替代標記的缺乏
    • 不完全的研究資金與不確實長期性的流程
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各治療藥物
    • 膽鹼酯酶抑制劑
    • NMDA受體拮抗劑
    • 其他
  • 各診斷法
    • 腦成像
    • 腦脊髓液(CSF)檢驗
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併及收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • F. Hoffmann-La Roche
  • Novartis
  • Merck & Co.
  • Pfizer Inc
  • Eisai
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lily & Co
  • Amarantus Bioscience Holdings
  • DiaGenic ASA
  • Navidea Biopharmaceuticals Holdings Inc.
  • GE Healthcare

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53669

Market Overview

The global Alzheimer's disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.

Alzheimer's disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer's disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer's disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.

Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer's disease diagnostics and therapeutics market, globally.

Scope of the Report

As per the scope of the report, Alzheimer's disease (AD) is a progressive, degenerative disorder that attacks the brain's nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.

Key Market Trends

Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment

In the therapeutics segment of the Alzheimer's disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.

Cholinesterase inhibitors are used for the treatment of Alzheimer's. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer's disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.

The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for Alzheimer's disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer's disease diagnostics and therapeutics market. According to the Alzheimer's Association, more than 5 million Americans suffer from Alzheimer's, as of 2017. The United States is considered to be the global leader in Alzheimer's disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer's disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.

Competitive Landscape

The Alzheimer's disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer's disease diagnostics and therapeutics market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Investment in Biomarkers for Drug Development
    • 4.2.2 Increasing Pipeline Drug Development
    • 4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
    • 4.2.4 Emerging Novel Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 Early Diagnosis of the Indication is Challenging
    • 4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
    • 4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
    • 4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutics
    • 5.1.1 Cholinesterase Inhibitors
    • 5.1.2 NMDA Receptor Antagonists
    • 5.1.3 Other Therapeutics
  • 5.2 By Diagnostics
    • 5.2.1 Brain Imaging
    • 5.2.2 CFS Test for Alzheimer's Disease
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-La Roche
    • 6.1.2 Novartis AG
    • 6.1.3 Merck & Co. Inc
    • 6.1.4 Pfizer Inc
    • 6.1.5 Eisai Co. Ltd
    • 6.1.6 Biogen Inc
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Eli Lilly & Company
    • 6.1.9 Amarantus Bioscience Holdings Inc
    • 6.1.10 Diagenic ASA
    • 6.1.11 Navidea Biopharmaceuticals
    • 6.1.12 GE Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS